Microbial gatekeepers: unraveling the role of the gut microbiota enzyme DPP4 in diabetes management

Lijuan Liao; Fan Lin; Jiangtao Gao

doi:10.1016/j.tibs.2023.09.005

Microbial gatekeepers: unraveling the role of the gut microbiota enzyme DPP4 in diabetes management

Trends Biochem Sci. 2024 Feb;49(2):99-100. doi: 10.1016/j.tibs.2023.09.005. Epub 2023 Sep 26.

Authors

Lijuan Liao¹, Fan Lin², Jiangtao Gao³

Affiliations

¹ Key Laboratory of Biopesticides and Chemical Biology of the Ministry of Education, College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, PR China; State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, PR China.
² School of Integrated Traditional Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, PR China.
³ Key Laboratory of Biopesticides and Chemical Biology of the Ministry of Education, College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, PR China. Electronic address: jgaotao@gmail.com.

PMID: 37770288
DOI: 10.1016/j.tibs.2023.09.005

Abstract

Wang et al. identified dipeptidyl peptidase 4 (DPP4) as a gut microbe-derived enzyme that impacts on host glucose metabolism. They further introduced a novel therapeutic, daurisoline-d4 (Dau-d4), a selective microbial DPP4 (mDPP4) inhibitor that shows promise in improving glucose tolerance, highlighting the potential of therapies that target both host enzymes and gut microbial enzymes.

Keywords: DPP4; daurisoline-d4; diabetes management; gut microbiota.

MeSH terms

Diabetes Mellitus*
Dipeptidyl Peptidase 4 / metabolism
Dipeptidyl-Peptidase IV Inhibitors* / pharmacology
Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
Gastrointestinal Microbiome*
Humans

Substances

Dipeptidyl Peptidase 4
Dipeptidyl-Peptidase IV Inhibitors